Skip to content
Disclosery

BOONE CAPITAL MANAGEMENT LLC

Follow

13F filer, CIK 1882053, ATLANTA, GA

BOONE CAPITAL MANAGEMENT LLC reported $326,408,252 across 13 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 90.65% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001214659-26-006448

Period
2026-03-31
Reported value
$326M
Holdings
13
Top 10 weight
90.65%
New
5
Sold out
7

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TFXnew+278,792$33.3M
GRDNnew+631,193$23.8M
AZNnew+110,101$21.7M
AVNSnew+1,184,909$16.6M
CIadded+41,069$11M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NBIXexited-151,815-$21.5M
AZNexited-220,201-$20.2M
HQYexited-212,856-$19.5M
LIVNexited-288,895-$17.8M
RAPTexited-470,456-$15.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001214659-26-006448, largest first. % of portfolio is the value over $326,408,252, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MIRMMIRUM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 543,843 shares; 2024Q4: 581,843 shares; 2025Q1: 603,318 shares; 2025Q2: 641,448 shares; 2025Q3: 535,732 shares; 2025Q4: 421,236 shares; 2026Q1: 421,236 shares 421,236$38.9M11.92%0Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 417,833 shares; 2025Q4: 417,833 shares; 2026Q1: 500,522 shares 500,522$37.6M11.51%+82,689Timeline
CITHE CIGNA GROUPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 131,926 shares; 2024Q4: 85,861 shares; 2025Q1: 70,859 shares; 2025Q2: 35,600 shares; 2025Q3: 82,972 shares; 2025Q4: 96,453 shares; 2026Q1: 137,522 shares 137,522$36.7M11.24%+41,069Timeline
MDTMEDTRONIC PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 393,737 shares; 2025Q2: 428,789 shares; 2025Q3: 428,789 shares; 2025Q4: 428,789 shares; 2026Q1: 398,065 shares 398,065$34.5M10.57%-30,724Timeline
TFXTELEFLEX INCORPORATEDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 278,792 shares 278,792$33.3M10.22%newTimeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 327,279 shares; 2025Q2: 447,449 shares; 2025Q3: 328,546 shares; 2025Q4: 411,880 shares; 2026Q1: 547,871 shares 547,871$30.9M9.48%+135,991Timeline
GRDNGUARDIAN PHARMACY SVCS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 631,193 shares 631,193$23.8M7.28%newTimeline
AZNASTRAZENECA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 110,101 shares 110,101$21.7M6.65%newTimeline
UNHUNITEDHEALTH GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 58,112 shares; 2025Q3: 58,112 shares; 2025Q4: 61,762 shares; 2026Q1: 79,226 shares 79,226$21.4M6.57%+17,464Timeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 460,282 shares; 2025Q4: 184,963 shares; 2026Q1: 228,829 shares 228,829$17M5.21%+43,866Timeline
AVNSAVANOS MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,184,909 shares 1,184,909$16.6M5.09%newTimeline
KODKODIAK SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 715,877 shares; 2025Q4: 503,830 shares; 2026Q1: 281,332 shares 281,332$10.7M3.29%-222,498Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares 200,000$3.2M0.98%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
NBIXNEUROCRINE BIOSCIENCES INC151,815$21.5Mshares
AZNASTRAZENECA PLC-SPONS ADR220,201$20.2Mshares
HQYHEALTHEQUITY INC212,856$19.5Mshares
LIVNLIVANOVA PLC288,895$17.8Mshares
RAPTRAPT THERAPEUTICS INC470,456$15.9Mshares
TYRATYRA BIOSCIENCES INC398,482$10.5Mshares
WVEWAVE LIFE SCIENCES LTD352,144$5.99Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001214659-26-006448 base2026-05-15acceptance time not in the bulk data set